Find a Clinical Trial
|Protocol||Trial Name and Objective|
Accelerated, Hypofractionated Post-Mastectomy Radiation Therapy in Women with Breast Cancer: A Phase II Trial
This study is a non-randomized, single arm study of female patients with invasive carcinoma of the breast who have had (or will have) a mastectomy followed by radiation therapy. The term 'accelerated' means that a higher radiation dose per treatment will be delivered over a shorter period of time (compared to the standard). Prior studies suggest that the accelerated radiation scheme used in this study is comparable to the standard or conventional whole breast radiation. That is, the evidence points to accelerated treatments may work at least as well as the longer, standard treatments. Along with measuring the recurrence outcomes, we will be measuring treatment side effects and cosmesis (how well the study treatment plan preserves the appearance of your surgically reconstructed breast).
Stereotactic Hypofractionated Accelerated Radiation and Prostatectomy in Patients with Elevated Risk (The SHARPER Trial - A Phase One Study)
1. Purpose/Specific Objectives
Significance of Single Nucleotide Polymorphisms in Breast Cancer Patients Undergoing Radiation Therapy
In a cohort of approximately 250 women, diagnosed with breast cancer and treated with breast conserving surgery or mastectomy and radiation we will evaluate the frequency of this polymorphism (SNP309). We will correlate the polymorphism status with other clinical, pathologic and genetic information we have on these 250 women, including but not limited to stage, age of onset of disease, receptor status, her2 status, and the status of BRCA1 and BRCA2. We will recruit additional patients with a new diagnosis of breast cancer to correlate the status of SNP309 with other clinical and pathological variables.
The Possible Role of ERCC1 in Determining Patterns of Recurrence after Chemoradiation for Lung Cancer
This study intends to characterize ERCC1 overexpression in predicting local recurrence of non-metastatic lung cancer and pancreas cancer treated with radiation therapy (RT) with or without chemotherapy. It is hypothesized that higher ERCC1 levels would allow for improved repair capacity and higher chance of local recurrence after radiation therapy
COG-ACNS0331: A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial
To determine whether reducing the craniospinal dose of radiation therapy to 18.00 Gy in children 3-7 years of age does not compromise event-free survival and overall survival as compared to treatment with
COG-AALL0434: Intensified Methotrexate, Nelarabine (Compound 506U78; IND # 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma
Subjects diagnosed with T-cell acute lymphoblastic leukemia (ALL) will be asked to participate in this study. Although event free survival and overall survival continue to increase for children and young adults with T-cell ALL, relapses (the disease coming back) continue to be a common cause of treatment failure. There is evidence that a new drug called Nelarabine (Compound 506U78) and high dose methotrexate are effective in preventing relapse in T-cell ALL. To specifically address treatment failures associated with high-risk T-cell ALL, this study will test the safety of these two drugs. Subjects will be randomized into one of four treatment groups - standard therapy with nelarabine, standard therapy without nelarabine, high-dose methotrexate with nelarabine and high-dose methotrexate without nelarabine. Subjects in all treatment groups will receive cranial radiation therapy (CRT). Subjects randomized to treatment groups A & B will receive CRT during the consolidation stage of treatment. Subjects randomized to treatment groups C & D will receive CRT during the delayed intensification stage of treatment.
COG-ARST08P1 : A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC # 742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma
1. To determine the feasibility of administering IMC-A12 in combination with a multi-agent intensive chemotherapy regimen for the treatment of high-risk rhabdomyosarcoma.
COG ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
1. To determine the event free survival (EFS) and overall survival (OS) of children with completely resected ependymoma treated with post-operative conformal radiation therapy (cRT) and then randomized to receive or not receive four cycles of post radiation maintenance chemotherapy with vincristine, cisplatin, etoposide and cyclophosphamide (VCEC).
ECOG E6508: A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation
The primary objective is to determine the safety of combination therapy with chemoradiation, followed by consolidation, finally followed by L-BLP25 and bevacizumab for patients with non-squamous, locally advanced NSCLC.
RTOG 1205: Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
To establish an improvement in overall survival in recurrent GBM patients receiving bevacizumab and re-irradiation compared with patients receiving bevacizumab alone.